Probi: How industry can support GLP-1 users while navigating regulatory scrutiny
04 May 2026 | Probi
Brandy Webb, N.D., Scientific Affairs manager at Probi, explores how GLP-1 therapies are reshaping nutrition science, product innovation, and metabolic health strategies. Seeing the microbiome as a metabolic infrastructure for GLP-1 signaling, she reveals actionable science that brands should be prioritizing now. Webb also touches on companion solutions backed by clinical evidence and how companies might navigate regulatory scrutiny tightening around peptides and grey-market products.
